Considering that the PD-1/PD-L1 interaction represents a pivotal immune-suppressive signaling pathway that facilitates tumor progression, we wondered if a treatment of mt21 ASO-4 or mt29 ASO-4 that targeted tumor cells could enhance the killing effect of immune cells on tumor cells. Here, CD274 is linked to neoplasm.